Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Alchemab Therapeutics has raised €98M across 3 funding rounds from 8 investors, most recently a Series A round in Jul 2026. Based in London, UK; founded 2019; active in Healthtech. Data as of 6 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-09 | Series A | €29M | British Business Bank | View deal → |
| 2025-09-09 | Series A | — | DCVC Bio,Lightstone Ventures,Lilly,Ono Venture Investment (OVI),RA Capital,SV Health Investors | View deal → |
| 2021-04-15 | Series A | €69M | RA Capital Management | View deal → |
